Alexander Seifalian, Professor of
Nanotechnology and Regenerative Medicine worked at the Royal Free Hospital and
University College London for over 26 years, during this time he spent a year
at Harvard Medical School looking at caused of cardiovascular diseases and a
year at Johns Hopkins Medical School looking at the treatment of liver cancer.
He published more than 647 peer-reviewed research papers and registered 14 UK
and International patents. On editorial boards of 41 journals. He is currently
CEO of NanoRegMed Ltd, working on the commercialisation of his research. During his career, Prof Seifalian has led and
managed many large projects with successful outcomes in terms of
commercialisation and translation to patients. In 2007 he was awarded the top
prize in the field for the development of nanomaterials and technologies for
cardiovascular implants by Medical Future Innovation, and in 2009 he received a
Business Innovation Award from UK Trade & Investment (UKTI). He was the
European Life Science Awards’ Winner of Most Innovative New Product 2012 for
the “synthetic trachea”. Prof Seifalian won the Nanosmat Prize in 2013 and in
2016 he received the Distinguish Research Award in recognition of his
outstanding work in regenerative medicine from Heals Healthy Life Extension
Society. His achievements include the development of the world first synthetic
trachea, lacrimal drainage conduit, and vascular bypass graft using
nanocomposite materials, bioactive molecules and stem cell technology. He has
over 15,000 media report from his achievement; include BBC, ITV, WSJ, CNN, and
many more. Currently, he is working on the development and commercialisation of
human organs using graphene-based nanocomposite materials and stem cells
technology. He has commercialised a novel functionalised graphene oxide for
medical and other industrial applications.